MX9800883A - Composiciones de agente terapeutico estabilizadas por conjugacion, suministro y formulaciones de diagnostico. - Google Patents

Composiciones de agente terapeutico estabilizadas por conjugacion, suministro y formulaciones de diagnostico.

Info

Publication number
MX9800883A
MX9800883A MX9800883A MX9800883A MX9800883A MX 9800883 A MX9800883 A MX 9800883A MX 9800883 A MX9800883 A MX 9800883A MX 9800883 A MX9800883 A MX 9800883A MX 9800883 A MX9800883 A MX 9800883A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
insulin
polymer
coupled
another
Prior art date
Application number
MX9800883A
Other languages
English (en)
Other versions
MXPA98000883A (es
Inventor
Nnochiri Nkem Ekwuribe
Original Assignee
Protein Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Delivery Inc filed Critical Protein Delivery Inc
Publication of MX9800883A publication Critical patent/MX9800883A/es
Publication of MXPA98000883A publication Critical patent/MXPA98000883A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un complejo de agente terapéutico conjugado estabilizado que comprende un agente terapéutico acoplado conjugativamente a un polímero que incluye porciones lipofílicas e hidrofílicas. En un aspecto particular, la invencion comprende una composicion de insulina adecuada para administracion parenteral si como no parenteral, preferiblemente administracion oral o parenteral comprendiendo insulina acoplada covalentemente con un polímero que incluye: (i) una porcion de glicol de polialquileno lineal y (ii) una porcion lipofílica, en donde la insulina, la porcion de glicol de polialquileno lineal y la porcion lipofílica están dispuestas conformacionalmente en relacion una con la otra de manera que la insulina en la composicion tenga resistencia incrementada in vivo a la degradacion enzimática, en relacion con la insulina sola. Uno, dos o tres constituyentes poliméricos pueden estar unidos covalentemente a la molécula de agente terapéutico, siendo preferido un constituyente polimérico. Los conjugados de la invencion se emplean utilmente en aplicaciones terapéuticas así como no terapéuticas, v.gr., de diagnostico, y el agente terapéutico y polímero pueden estar acoplados covalentemente uno al otro, o alternativamente pueden estar acoplados asociativamente uno al otro, v. gr. por union de hidrogeno u otra relacion de union asociativa.
MXPA/A/1998/000883A 1995-07-31 1998-01-30 Composiciones de agente terapeutico estabilizadas por conjugacion, suministro y formulaciones de diagnostico MXPA98000883A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08509422 1995-07-31
US08/509,422 US5681811A (en) 1993-05-10 1995-07-31 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US609422 1996-03-01

Publications (2)

Publication Number Publication Date
MX9800883A true MX9800883A (es) 1998-09-30
MXPA98000883A MXPA98000883A (es) 1998-11-16

Family

ID=

Also Published As

Publication number Publication date
CN1192690A (zh) 1998-09-09
CA2227891C (en) 2009-04-14
IL123106A0 (en) 1998-09-24
JPH11511131A (ja) 1999-09-28
EP0841936A1 (en) 1998-05-20
CA2227891A1 (en) 1997-02-13
AU698944B2 (en) 1998-11-12
US5681811A (en) 1997-10-28
EP0841936A4 (en) 2001-09-26
CN1182870C (zh) 2005-01-05
AU6640996A (en) 1997-02-26
WO1997004796A1 (en) 1997-02-13

Similar Documents

Publication Publication Date Title
CA2227891A1 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
IL109619A0 (en) Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
BR122018071968B8 (pt) conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2003068144A3 (en) Cytotoxic agents
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
WO2001051510A3 (en) G-csf conjugates
WO2002062396A3 (en) Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
AU2003221291A1 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
WO2004022099A3 (en) Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
AU3470600A (en) Compositions and methods for drug delivery
YU54301A (sh) Konjugati gcsf
EP2260872A3 (en) Polymer conjugates of interferon beta-1A and uses thereof
SI1180121T1 (en) Long lasting insulinotropic peptides
MXPA03000190A (es) Composicion para el suministro del factor de crecimiento hamtopoyetico.
WO2003084470A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
KR890701736A (ko) 과산화물 분자변위보효소의 포합체
UA100967C2 (ru) Конъюгаты нейбластина с полимерами и способы их применения
CA2723823A1 (en) Conjugates for the treatment of mesothelioma
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
EP1351709B8 (en) Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
Forte et al. Characterization of naproxen–polymer conjugates for drug-delivery